Horizon Therapeutics Public Stock Forecast, Price & News

-0.66 (-0.70 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.21 million shs
Average Volume1.78 million shs
Market Capitalization$20.97 billion
P/E Ratio80.42
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive HZNP News and Ratings via Email

Sign-up to receive the latest news and ratings for Horizon Therapeutics Public and its competitors with MarketBeat's FREE daily newsletter.

Horizon Therapeutics Public logo

About Horizon Therapeutics Public

Horizon Therapeutics Public Limited Company focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. It operates in two segments, Orphan and Inflammation. Its medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare lysosomal storage disorder; ACTIMMUNE for chronic granulomatous disease and severe malignant osteopetrosis; RAYOS for the treatment of rheumatoid arthritis (RA), ankylosing spondylitis (AS), polymyalgia rheumatica, primary systemic amyloidosis, asthma, chronic obstructive pulmonary disease, systemic lupus erythematosus, and other conditions; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company also offers PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis (OA) of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; and VIMOVO for the relief of signs and symptoms of OA, RA, and AS to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

2.05 out of 5 stars

Medical Sector

58th out of 2,096 stocks

Pharmaceutical Preparations Industry

26th out of 830 stocks

Analyst Opinion: 3.4Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Horizon Therapeutics Public (NASDAQ:HZNP) Frequently Asked Questions

Is Horizon Therapeutics Public a buy right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last year. There are currently 1 sell rating and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Horizon Therapeutics Public stock.
View analyst ratings for Horizon Therapeutics Public
or view top-rated stocks.

What stocks does MarketBeat like better than Horizon Therapeutics Public?

Wall Street analysts have given Horizon Therapeutics Public a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Horizon Therapeutics Public wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Horizon Therapeutics Public's next earnings date?

Horizon Therapeutics Public is scheduled to release its next quarterly earnings announcement on Wednesday, August 4th 2021.
View our earnings forecast for Horizon Therapeutics Public

How were Horizon Therapeutics Public's earnings last quarter?

Horizon Therapeutics Public Limited (NASDAQ:HZNP) released its quarterly earnings data on Wednesday, May, 5th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.07 by $0.04. The biopharmaceutical company had revenue of $342.41 million for the quarter, compared to analysts' expectations of $389.51 million. Horizon Therapeutics Public had a trailing twelve-month return on equity of 22.28% and a net margin of 12.81%. The company's revenue was down 3.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.40 earnings per share.
View Horizon Therapeutics Public's earnings history

How has Horizon Therapeutics Public's stock price been impacted by Coronavirus (COVID-19)?

Horizon Therapeutics Public's stock was trading at $30.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, HZNP shares have increased by 205.8% and is now trading at $93.29.
View which stocks have been most impacted by COVID-19

What guidance has Horizon Therapeutics Public issued on next quarter's earnings?

Horizon Therapeutics Public issued an update on its FY 2021 earnings guidance on Wednesday, May, 26th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $2.75 billion-$2.85 billion, compared to the consensus revenue estimate of $2.81 billion.

What price target have analysts set for HZNP?

12 brokerages have issued 12 month price objectives for Horizon Therapeutics Public's stock. Their forecasts range from $90.00 to $125.00. On average, they expect Horizon Therapeutics Public's share price to reach $111.36 in the next twelve months. This suggests a possible upside of 19.4% from the stock's current price.
View analysts' price targets for Horizon Therapeutics Public
or view top-rated stocks among Wall Street analysts.

Who are Horizon Therapeutics Public's key executives?

Horizon Therapeutics Public's management team includes the following people:
  • Mr. Timothy P. Walbert, Chairman, Pres & CEO (Age 54, Pay $5.48M)
  • Mr. Paul W. Hoelscher, Exec. VP & CFO (Age 56, Pay $1.88M)
  • Mr. Barry J. Moze, Exec. VP & Chief Admin. Officer (Age 67, Pay $1.71M)
  • Dr. Jeffrey W. Sherman M.D., F.A.C.P., Exec. VP & Chief Medical Officer (Age 66, Pay $1.55M)
  • Mr. Andy Pasternak, Exec. VP & Chief Strategy Officer (Age 50, Pay $1.79M)
  • Mr. Miles W. McHugh, Chief Accounting Officer & Sr. VP (Age 56)
  • Ms. Tina E. Ventura, Sr. VP of Investor Relations
  • Mr. Brian K. Beeler, Exec. VP & Gen. Counsel (Age 48)
  • Mr. Timothy Ayers, Chief Compliance Officer & VP
  • Mr. Geoffrey M. Curtis, Exec. VP of Corp. Affairs & Chief Communications Officer (Age 46)

What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO?

70 employees have rated Horizon Therapeutics Public CEO Timothy Walbert on Timothy Walbert has an approval rating of 73% among Horizon Therapeutics Public's employees.

Who are some of Horizon Therapeutics Public's key competitors?

What other stocks do shareholders of Horizon Therapeutics Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).

What is Horizon Therapeutics Public's stock symbol?

Horizon Therapeutics Public trades on the NASDAQ under the ticker symbol "HZNP."

Who are Horizon Therapeutics Public's major shareholders?

Horizon Therapeutics Public's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.86%), Janus Henderson Group PLC (3.38%), JPMorgan Chase & Co. (2.51%), Renaissance Technologies LLC (2.32%), William Blair Investment Management LLC (1.85%) and Orbimed Advisors LLC (1.40%). Company insiders that own Horizon Therapeutics Public stock include Barry Moze, Brian K Beeler, Daniel A Camardo, Geoffrey M Curtis, Irina Konstantinovsky, James Samuel Shannon, Jeff Kent, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Timothy P Walbert, Vikram Karnani and William F Daniel.
View institutional ownership trends for Horizon Therapeutics Public

Which institutional investors are selling Horizon Therapeutics Public stock?

HZNP stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Viking Global Investors LP, William Blair Investment Management LLC, Perceptive Advisors LLC, D. E. Shaw & Co. Inc., Janus Henderson Group PLC, Polar Capital Holdings Plc, and UBS Group AG. Company insiders that have sold Horizon Therapeutics Public company stock in the last year include Barry Moze, Daniel A Camardo, Geoffrey M Curtis, Irina Konstantinovsky, Jeff Kent, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Timothy P Walbert, Vikram Karnani, and William F Daniel.
View insider buying and selling activity for Horizon Therapeutics Public
or view top insider-selling stocks.

Which institutional investors are buying Horizon Therapeutics Public stock?

HZNP stock was purchased by a variety of institutional investors in the last quarter, including Waddell & Reed Financial Inc., Ameriprise Financial Inc., BlackRock Inc., Oak Ridge Investments LLC, Principal Financial Group Inc., BNP Paribas Arbitrage SA, Clearbridge Investments LLC, and Lord Abbett & CO. LLC.
View insider buying and selling activity for Horizon Therapeutics Public
or or view top insider-buying stocks.

How do I buy shares of Horizon Therapeutics Public?

Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Horizon Therapeutics Public's stock price today?

One share of HZNP stock can currently be purchased for approximately $93.29.

How much money does Horizon Therapeutics Public make?

Horizon Therapeutics Public has a market capitalization of $20.97 billion and generates $2.20 billion in revenue each year. The biopharmaceutical company earns $389.80 million in net income (profit) each year or $3.88 on an earnings per share basis.

How many employees does Horizon Therapeutics Public have?

Horizon Therapeutics Public employs 1,395 workers across the globe.

Does Horizon Therapeutics Public have any subsidiaries?

The following companies are subsidiares of Horizon Therapeutics Public: Andromeda Biotech Limited, Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, HZNP USA LLC, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Aon Limited, Horizon Pharma Dó Limited, Horizon Pharma Israel Holding Corp. Ltd, Horizon Pharma Rheumatology LLC, Horizon Pharma Trí Limited, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Schweiz GmbH, Horizon Therapeutics Services LLC, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, and River Vision Development Corp..

When was Horizon Therapeutics Public founded?

Horizon Therapeutics Public was founded in 2008.

What is Horizon Therapeutics Public's official website?

The official website for Horizon Therapeutics Public is

Where are Horizon Therapeutics Public's headquarters?

Horizon Therapeutics Public is headquartered at 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6.

How can I contact Horizon Therapeutics Public?

Horizon Therapeutics Public's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at 011-353-1772-2100 or via email at [email protected]

This page was last updated on 6/12/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.